Futibatinib, a potent, selective and irreversible small‐molecule inhibitor of FGFR1/2/3/4, inhibits the growth of FGFR abnormal cells and tumour xenografts [52], shows positive responses in trials of patients with advanced solid tumours [53] and is approved for patients with advanced intrahepatic cholangiocarcinomas that exhibit abnormal FGFR and who have failed at least one line of therapy (www.fda.gov/drugs). The gene discussed is FGFR1; the disease is cholangiocarcinoma.